This promotional webinar is organised and fully funded by Bayer. Prescribing information for any Bayer products mentioned can be found at the bottom of the page and will also be available during the webinar.

The Next Chapter: Mirena

Bayer is delighted to announce the license extension to Mirena® in contraception which now is 8 years and the symptom-led extension in idiopathic Heavy Menstrual Bleeding (HMB) for up to 8 years should symptoms not return after 5 years of use.1
Wednesday 7th February 2024, 7:30-8:30pm


Dr Diana Mansour

Consultant in Community Gynaecology and Reproductive Healthcare

Read full biography >

Dr Paula Briggs

Consultant in Sexual and Reproductive Health

Read full biography >

Learning Outcomes

  • Understand Mirena’s background – supporting Women across three licensed indications
  • Understand the new 8 year license extension in contraception and symptom-led HMB and the data to support it
  • Be able to apply the license extension, and understand how this will impact your practise and shape the Women’s Health landscape

1. Mirena SmPC 2024

Endometrial protection indication has not changed from 4 years.